Quarterly report pursuant to Section 13 or 15(d)

Significant Agreements (Details)

v3.22.2.2
Significant Agreements (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Aug. 31, 2022
Jul. 14, 2022
Feb. 09, 2022
Jan. 06, 2022
Jul. 13, 2021
Jul. 27, 2022
Jun. 29, 2022
Jul. 19, 2021
Sep. 30, 2018
Oct. 30, 2017
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Sep. 30, 2022
Jul. 01, 2017
Significant Agreements (Details) [Line Items]                              
Company agreement description                           According to the terms of the agreement Unicycive will pay the vendor $2 million in the first calendar year when the net revenue reaches $10 million from sales of Renazorb following its approval by the FDA and commercial supply of the product by the vendor (First Payment). Thereafter, the Company will pay $2 million per year for four consecutive years, after the first year’s payment, for the total payments of $10 million, provided all commercial supplies are continued to be manufactured and supplied by the vendor.  
License agreement                   No payments were made upon execution of the agreement but rather payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. At the time the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter.          
Company issued shares (in Shares)                             62,181
Common stock valued                       $ 22,271,000      
Public market capitalization         $ 50,000,000                    
Anti-dilution shares of common stock (in Shares)         438,374                    
Research and development expenses                           $ 2,200,000  
Purchase agreement, description                           The Company is also required to pay Spectrum 40% of all of the Company’s sublicense income for any sublicense granted to certain sublicensees during the first 12 months after the Closing Date (as that term is defined in the Renazorb Purchase Agreement) and 20% of all other sublicense income. The Company’s payment obligations to Spectrum will expire on the twentieth (20th) anniversary of the Closing Date of the Renazorb Purchase Agreement.  
Upfront payment amount $ 1,000,000                            
Spectrum agreement percentage                     20.00%     20.00%  
Prepaid expenses                     $ 800,000     $ 800,000  
Accounts payable or accrued expense                     800,000     800,000  
Remaining services budget                     100,000     100,000  
Tiered royalties percentage   10.00%                          
Syneos Health LLC [Member]                              
Significant Agreements (Details) [Line Items]                              
Research related payments                         $ 1,200,000    
Prepaid expenses                         $ 2,000,000    
Quotient Sciences Limited [Member]                              
Significant Agreements (Details) [Line Items]                              
Research related payments                           1,300,000  
Prepaid expenses                     500,000     500,000  
Celerion [Member]                              
Significant Agreements (Details) [Line Items]                              
Research and development expenses           $ 2,700,000                  
Research related payments                           800,000  
Prepaid expenses                     1,400,000     1,400,000  
Accounts payable                     600,000     600,000  
Spectrum Pharmaceuticals, Inc. [Member]                              
Significant Agreements (Details) [Line Items]                              
Company issued shares (in Shares)                 313,663            
Common stock valued                 $ 4,000            
Market capitalization                 $ 50,000,000            
Spectrum Pharmaceuticals, Inc. [Member] | Investment [Member]                              
Significant Agreements (Details) [Line Items]                              
Interest on ownership                 4.00%            
Syneos Health LLC [Member]                              
Significant Agreements (Details) [Line Items]                              
Research and development expenses               $ 2,300,000              
Quotient Sciences Limited [Member]                              
Significant Agreements (Details) [Line Items]                              
Research and development expenses       $ 3,700,000                      
CBCC Global Research Inc [Member]                              
Significant Agreements (Details) [Line Items]                              
Research and development expenses     $ 1,400,000                        
Research related payments                           300,000  
Related expense                           400,000  
Inotiv [Member]                              
Significant Agreements (Details) [Line Items]                              
Research and development expenses             $ 1,000,000                
Research related payments                           300,000  
Prepaid expenses                     $ 200,000     $ 200,000  
Lee’s Pharmaceutical (HK) Limited [Member]                              
Significant Agreements (Details) [Line Items]                              
Research and development expenses   $ 1,000,000                          
Research related payments   $ 1,000,000                          
Tiered royalties percentage   7.00%